{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:17Z","timestamp":1784408837633,"version":"3.55.0"},"reference-count":25,"publisher":"CSIRO Publishing","issue":"4","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Flibanserin, a centrally acting 5-HT1A agonist and 5-HT2A antagonist, is the first approved therapy for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Despite its clinical availability, post-marketing data on real-world safety remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective pharmacovigilance analysis was conducted using the US Food and Drug Administration Adverse Event Reporting System from 2016 to 2025. Duplicate removal, data harmonization and standardized MedDRA coding were applied. Only reports in which flibanserin was designated as the primary suspect drug were included. Disproportionality analyses using proportional reporting ratio, reporting odds ratio, information component and empirical Bayes geometric mean algorithms identified flibanserin-associated safety signals. Sensitivity analyses were conducted according to recorded concomitant medication status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1702 adverse event reports were identified, with 95% involving women. Most events were non-serious and occurred within the first week of therapy (median onset: 3\u00a0days). Prominent signals were nervous system and psychiatric disorders, notably somnolence, dizziness, insomnia and fatigue. Additional signals included hypotension, orthostatic hypotension and product use in unapproved populations, suggesting off-label exposure. Central nervous system-related signals remained directionally consistent in flibanserin-only and concomitant-medication cohorts, whereas hypotension was prominent among reports with recorded concomitant medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Flibanserin\u2019s real-world safety profile is largely consistent with preapproval data, dominated by early-onset, reversible central nervous system reactions linked to its serotonergic mechanism. However, persistent hypotension and off-label or product-use-related reports underscore the need for continued pharmacovigilance, clinician education, and strict adherence to Risk Evaluation and Mitigation Strategy requirements to maintain an optimal benefit\u2013risk balance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/sh25248","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:54:32Z","timestamp":1783299272000},"source":"Crossref","is-referenced-by-count":1,"title":["Flibanserin safety in real-world use: a decade of US Food and Drug Administration Adverse Event Reporting System pharmacovigilance evidence"],"prefix":"10.1071","volume":"23","author":[{"given":"Guojun","family":"Liang","sequence":"first","affiliation":[{"name":"AThe GuangZhou Affiliated Hospital of Jinan University (Huadu District People\u2019s Hospital of Guangzhou), 48 Xinhua Road, Huadu District, Guangzhou, Guangdong 510800, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Huang","sequence":"additional","affiliation":[{"name":"AThe GuangZhou Affiliated Hospital of Jinan University (Huadu District People\u2019s Hospital of Guangzhou), 48 Xinhua Road, Huadu District, Guangzhou, Guangdong 510800, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haokui","family":"Wang","sequence":"additional","affiliation":[{"name":"AThe GuangZhou Affiliated Hospital of Jinan University (Huadu District People\u2019s Hospital of Guangzhou), 48 Xinhua Road, Huadu District, Guangzhou, Guangdong 510800, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[{"name":"AThe GuangZhou Affiliated Hospital of Jinan University (Huadu District People\u2019s Hospital of Guangzhou), 48 Xinhua Road, Huadu District, Guangzhou, Guangdong 510800, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8347-0942","authenticated-orcid":true,"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"AThe GuangZhou Affiliated Hospital of Jinan University (Huadu District People\u2019s Hospital of Guangzhou), 48 Xinhua Road, Huadu District, Guangzhou, Guangdong 510800, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"6","key":"2026070520514264800_R1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/jmwh.13283","article-title":"Hypoactive sexual desire disorder in women: physiology, assessment, diagnosis, and treatment.","volume":"66","author":"Pettigrew","year":"2021","journal-title":"J Midwifery Womens Health"},{"issue":"11","key":"2026070520514264800_R2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2165\/00023210-200216110-00003","article-title":"Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment.","volume":"16","author":"Warnock","year":"2002","journal-title":"CNS Drugs"},{"issue":"11","key":"2026070520514264800_R3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49690","article-title":"Understanding hypoactive sexual desire disorder (HSDD) in women: etiology, diagnosis, and treatment.","volume":"15","author":"Ronghe","year":"2023","journal-title":"Cureus"},{"issue":"13","key":"2026070520514264800_R4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/archinte.168.13.1441","article-title":"Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women.","volume":"168","author":"West","year":"2008","journal-title":"Arch Intern Med"},{"issue":"4","key":"2026070520514264800_R5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00213-013-3194-6","article-title":"Brain neuronal activation induced by flibanserin treatment in female rats.","volume":"230","author":"Gelez","year":"2013","journal-title":"Psychopharmacology"},{"issue":"7","key":"2026070520514264800_R6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/sj.bjp.0705341","article-title":"Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors.","volume":"139","author":"Invernizzi","year":"2003","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2026070520514264800_R7","first-page":"237","article-title":"Flibanserin (Addyi): the first FDA-approved treatment for female sexual interest\/arousal disorder in premenopausal women.","volume":"42","author":"English","year":"2017","journal-title":"Pharm Therap"},{"issue":"7","key":"2026070520514264800_R8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"2026070520514264800_R9","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"issue":"1","key":"2026070520514264800_R10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-80067-0","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag.","volume":"14","author":"Xue","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"2026070520514264800_R11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2026070520514264800_R12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2026070520514264800_R13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2026070520514264800_R14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020242","article-title":"Safety surveillance of pneumococcal vaccine using three algorithms: disproportionality methods, empirical Bayes geometric mean, and tree-based scan statistic.","volume":"8","author":"Lee","year":"2020","journal-title":"Vaccines"},{"issue":"5","key":"2026070520514264800_R15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40264-015-0389-2","article-title":"Maximizing the post-approval safety of flibanserin: a role for regulators, clinicians, and patients.","volume":"39","author":"Baksh","year":"2016","journal-title":"Drug Saf"},{"issue":"1","key":"2026070520514264800_R16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1743-6109.2010.02032.x","article-title":"Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder.","volume":"8","author":"Stahl","year":"2011","journal-title":"J Sex Med"},{"issue":"1","key":"2026070520514264800_R17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jsxm.2017.11.005","article-title":"Safety of flibanserin in women treated with antidepressants: a randomized, placebo-controlled study.","volume":"15","author":"Clayton","year":"2018","journal-title":"J Sex Med"},{"issue":"25","key":"2026070520514264800_R18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038542","article-title":"Role of flibanserin in managing hypoactive sexual desire disorder in women: a systematic review and meta-analysis.","volume":"103","author":"Kamrul-Hasan","year":"2024","journal-title":"Medicine"},{"issue":"2","key":"2026070520514264800_R19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/phrs.2000.0762","article-title":"Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors.","volume":"43","author":"Scandroglio","year":"2001","journal-title":"Pharmacol Res"},{"issue":"5","key":"2026070520514264800_R20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/jcpt.12563","article-title":"The pharmacodynamic effects of combined administration of flibanserin and alcohol.","volume":"42","author":"Stevens","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2026070520514264800_R21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/ipj.ipj_20_16","article-title":"Flibanserin: a controversial drug for female hypoactive sexual desire disorder.","volume":"27","author":"Baid","year":"2018","journal-title":"Ind Psychiatry J"},{"issue":"2","key":"2026070520514264800_R22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1056\/NEJMp1513686","article-title":"FDA approval of flibanserin\u2014treating hypoactive sexual desire disorder.","volume":"374","author":"Joffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2026070520514264800_R23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.sxmr.2018.10.003","article-title":"Evaluation of flibanserin safety: comparison with other serotonergic medications.","volume":"7","author":"Kingsberg","year":"2019","journal-title":"Sex Med Rev"},{"issue":"6","key":"2026070520514264800_R24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"4","key":"2026070520514264800_R25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40264-023-01397-6","article-title":"Sociodemographic characteristics of adverse event reporting in the USA: an ecologic study.","volume":"47","author":"Mu\u00f1oz","year":"2024","journal-title":"Drug Saf"}],"container-title":["Sexual Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25248\/1943835\/sh25248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/sh\/article-pdf\/doi\/10.1071\/SH25248\/1943835\/sh25248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:54:33Z","timestamp":1783299273000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/sh\/article\/23\/4\/SH25248\/274261\/Flibanserin-safety-in-real-world-use-a-decade-of"}},"subtitle":[],"editor":[{"given":"Kevan","family":"Wylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1071\/sh25248","relation":{},"ISSN":["1448-5028","1449-8987"],"issn-type":[{"value":"1448-5028","type":"print"},{"value":"1449-8987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"SH25248"}}